» Articles » PMID: 9731736

Plasma Sex Steroid Hormone Levels and Risk of Breast Cancer in Postmenopausal Women

Overview
Specialty Oncology
Date 1998 Sep 10
PMID 9731736
Citations 192
Authors
Affiliations
Soon will be listed here.
Abstract

Background: A positive relationship has generally been observed between plasma estrogen levels and breast cancer risk in postmenopausal women, but most of these studies have been small and few have evaluated specific estrogen fractions (such as percent bioavailable estradiol). In addition, few studies have evaluated plasma androgen levels in relation to breast cancer risk, and their results have been inconsistent. We prospectively evaluated relationships between sex steroid hormone levels in plasma and risk of breast cancer in postmenopausal women by use of a case-control study nested within the Nurses' Health Study.

Methods: Blood samples were collected during the period from 1989 through 1990. Among postmenopausal women not using hormone replacement therapy at blood collection (n = 11,169 women), 156 women were diagnosed with breast cancer after blood collection but before June 1, 1994. Two control subjects were selected per case subject and matched with respect to age, menopausal status, month and time of day of blood collection, and fasting status at the time of blood collection.

Results: From comparisons of highest and lowest (reference) quartiles, we observed statistically significant positive associations with risk of breast cancer for circulating levels of estradiol (multivariate relative risk [RR] = 1.91; 95% confidence interval [CI] = 1.06-3.46), estrone (multivariate RR = 1.96; 95% CI = 1.05-3.65), estrone sulfate (multivariate RR = 2.25; 95% CI = 1.23-4.12), and dehydroepiandrosterone sulfate (multivariate RR = 2.15; 95% CI = 1.11-4.17). We found no substantial associations with percent free or percent bioavailable estradiol, androstenedione, testosterone, or dehydroepiandrosterone. The positive relationships were substantially stronger among women with no previous hormone replacement therapy.

Conclusion: Our data, in conjunction with past epidemiologic and animal studies, provide strong evidence for a causal relationship between postmenopausal estrogen levels and the risk of breast cancer.

Citing Articles

Correlation of Androgen Receptor Expression With Ki67 Proliferative Index and Other Clinicopathological Characteristics in Invasive Mammary Carcinomas.

Keerthana Devi D, Pavithra V, Joseph L, Challa C Cureus. 2024; 16(10):e70867.

PMID: 39497884 PMC: 11534436. DOI: 10.7759/cureus.70867.


Circulating Estrogen Metabolites and Risk of Breast Cancer among Postmenopausal Women in the Nurses' Health Study.

Brantley K, Ziegler R, Craft N, Hankinson S, Eliassen A Cancer Epidemiol Biomarkers Prev. 2024; 34(3):375-384.

PMID: 39190182 PMC: 11865363. DOI: 10.1158/1055-9965.EPI-24-0577.


Metabolomic signatures of inflammation and metabolic dysregulation in relation to colorectal cancer risk.

Bever A, Hang D, Lee D, Tabung F, Ugai T, Ogino S J Natl Cancer Inst. 2024; 116(7):1126-1136.

PMID: 38430005 PMC: 11223797. DOI: 10.1093/jnci/djae047.


BMI and breast cancer risk around age at menopause.

Holle A, Adami H, Baglietto L, Berrington de Gonzalez A, Bertrand K, Blot W Cancer Epidemiol. 2024; 89:102545.

PMID: 38377945 PMC: 10942753. DOI: 10.1016/j.canep.2024.102545.


Plasma metabolites of a healthy lifestyle in relation to mortality and longevity: Four prospective US cohort studies.

Tessier A, Wang F, Liang L, Wittenbecher C, Haslam D, Eliassen A Med. 2024; 5(3):224-238.e5.

PMID: 38366602 PMC: 10940196. DOI: 10.1016/j.medj.2024.01.010.